July 25, 2013
Study Explains Why Africans May Be More Susceptible To Tuberculosis
Low expression of immune response gene 'MIF' increased risk for TB
A researcher from the Perelman School of Medicine at the University of Pennsylvania and colleagues have identified the genetic mutation in Africans with HIV that puts them at a much higher risk for tuberculosis (TB) infections.
Now, a new study, published this week in the online Early Edition of the Proceedings of the National Academy of Sciences, found that a commonly occurring polymorphism in an immune response gene called macrophage migration inhibitory factor (MIF) confers almost a two-and-a-half fold increased risk for severe TB in patients from Uganda who were co-infected with HIV.
Low-expressers of MIF were almost twice as common among people of African ancestry as Caucasians.
"These results help explain the increased incidence of TB among this group," said Rituparna Das, MD, PhD, an instructor in the division of Infectious Diseases at Penn Medicine. "Moreover, this is especially important in people co-infected with HIV, who have a compromised immune system and also constitute the major public health challenge of controlling TB."
TB's prevalence is rising because of drug resistance and an increasing number of patients who are co-infected with HIV. People with HIV and latent TB infection are at a much higher risk for progressing to active TB disease, so identifying patients earlier and getting them in preventative TB treatments is a priority.
"Therapies to augment MIF action are under development, and may provide a new tool to combat the global TB epidemic," said Dr. Das.
Recently, Dr. Das received funding from the Penn Center for AIDS Research to further examine MIF in Botswana. The pilot project will examine the distribution of MIF genetic polymorphisms among HIV co-infected patients with pulmonary TB from the Botswana-UPenn Partnership site.
"With the high degree of TB exposure in that community, we hope to identify which patients are more likely to go on to develop active TB disease, and in the future, target these patients for preventive therapies," said Dr. Das.
On the Net: